Focus: Axiom is a public biotechnology company specializing in AI-driven toxicity modeling, with a diversified pipeline spanning neurology, ophthalmology, infectious diseases, and gastroenterology. The company operates at a pre-revenue or early-revenue stage with limited disclosed financials.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
High-risk, early-stage AI biotech with compelling technology but critical cash constraints and execution uncertainty; suitable only for risk-tolerant candidates with equity optionality.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Axiom
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Axiom's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Axiom, GeneFab Partner to Advance Therapeutic Pipeline - Contract Pharma
Axiom, GeneFab Partner to Advance Therapeutic Pipeline Contract Pharma
Endo Axiom takes oral nanoparticle insulin into first-in-human trial - AllSci
Endo Axiom takes oral nanoparticle insulin into first-in-human trial AllSci
Natco Pharma Rights Issue 2026 Date, Price, Allotment, Ratio - IPO Watch
Natco Pharma Rights Issue 2026 Date, Price, Allotment, Ratio IPO Watch
Oral insulin drug achieves a critical milestone - The University of Sydney
Oral insulin drug achieves a critical milestone The University of Sydney
Symbiotec Pharmalab IPO Date, Review, Price, Allotment Details - IPO Watch
Symbiotec Pharmalab IPO Date, Review, Price, Allotment Details IPO Watch
Symbiotec Pharmalab IPO GMP, Grey Market Premium Today - IPO Watch
Symbiotec Pharmalab IPO GMP, Grey Market Premium Today IPO Watch
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Nontargeted LC-HRMS-Based Strategies as a Tool to Study the Behavior of Chemical Attribution Signatures of Organophosphorus in Complex Environmental Matrices.
Designing Butterfly-Inspired Architecture in Self-Assembled Hybrid Composites for Synergistic Structural Thermal Management.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo